Skip to main navigation Skip to search Skip to main content

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer

  • Kate Lawrenson
  • , Qiyuan Li
  • , Siddhartha Kar
  • , Ji Heui Seo
  • , Jonathan Tyrer
  • , Tassja J. Spindler
  • , Janet Lee
  • , Yibu Chen
  • , Alison Karst
  • , Ronny Drapkin
  • , Katja K.H. Aben
  • , Hoda Anton-Culver
  • , Natalia Antonenkova
  • , Helen Baker
  • , Elisa V. Bandera
  • , Yukie Bean
  • , Matthias W. Beckmann
  • , Andrew Berchuck
  • , Maria Bisogna
  • , Line Bjorge
  • Natalia Bogdanova, Louise A. Brinton, Angela Brooks-Wilson, Fiona Bruinsma, Ralf Butzow, Ian G. Campbell, Karen Carty, Jenny Chang-Claude, Georgia Chenevix-Trench, Anne Chen, Zhihua Chen, Linda S. Cook, Daniel W. Cramer, Julie M. Cunningham, Cezary Cybulski, Agnieszka Dansonka-Mieszkowska, Joe Dennis, Ed Dicks, Jennifer A. Doherty, Thilo Dörk, Andreas Du Bois, Matthias Dürst, Diana Eccles, Douglas T. Easton, Robert P. Edwards, Ursula Eilber, Arif B. Ekici, Peter A. Fasching, Brooke L. Fridley, Yu Tang Gao, Aleksandra Gentry-Maharaj, Graham G. Giles, Rosalind Glasspool, Ellen L. Goode, Marc T. Goodman, Jacek Grownwald, Patricia Harrington, Philipp Harter, Hanis Nazihah Hasmad, Alexander Hein, Florian Heitz, Michelle A.T. Hildebrandt, Peter Hillemanns, Estrid Hogdall, Claus Hogdall, Satoyo Hosono, Edwin S. Iversen, Anna Jakubowska, Paul James, Allan Jensen, Bu Tian Ji, Beth Y. Karlan, Susanne Kruger Kjaer, Linda E. Kelemen, Melissa Kellar, Joseph L. Kelley, Lambertus A. Kiemeney, Camilla Krakstad, Jolanta Kupryjanczyk, Diether Lambrechts, Sandrina Lambrechts, Nhu D. Le, Alice W. Lee, Shashi Lele, Arto Leminen, Jenny Lester, Douglas A. Levine, Dong Liang, Jolanta Lissowska, Karen Lu, Jan Lubinski, Lene Lundvall, Leon F.A.G. Massuger, Keitaro Matsuo, Valerie McGuire, John R. McLaughlin, Heli Nevanlinna, Ian McNeish, Usha Menon, Francesmary Modugno, Kirsten B. Moysich, Steven A. Narod, Lotte Nedergaard, Roberta B. Ness, Mat Adenan Noor Azmi, Kunle Odunsi, Sara H. Olson, Irene Orlow, Sandra Orsulic, Rachel Palmieri Weber, Celeste L. Pearce, Tanja Pejovic, Liisa M. Pelttari, Jennifer Permuth-Wey, Catherine M. Phelan, Malcolm C. Pike, Elizabeth M. Poole, Susan J. Ramus, Harvey A. Risch, Barry Rosen, Mary Anne Rossing, Joseph H. Rothstein, Anja Rudolph, Ingo B. Runnebaum, Iwona K. Rzepecka, Helga B. Salvesen, Joellen M. Schildkraut, Ira Schwaab, Thomas A. Sellers, Xiao Ou Shu, Yurii B. Shvetsov, Nadeem Siddiqui, Weiva Sieh, Honglin Song, Melissa C. Southey, Lara Sucheston, Ingvild L. Tangen, Soo Hwang Teo, Kathryn L. Terry, Pamela J. Thompson, Agnieszka Timorek, Ya Yu Tsai, Shelley S. Tworoger, Anne M. Van Altena, Els Van Nieuwenhuysen, Ignace Vergote, Robert A. Vierkant, Shan Wang-Gohrke, Christine Walsh, Nicolas Wentzensen, Alice S. Whittemore, Kristine G. Wicklund, Lynne R. Wilkens, Yin Ling Woo, Xifeng Wu, Anna H. Wu, Hannah Yang, Wei Zheng, Argyrios Ziogas, Alvaro Monteiro, Paul D. Pharoah, Simon A. Gayther, Matthew L. Freedman, David Bowtell, Penelope M. Webb, Anna DeFazio
  • University of Southern California
  • Xiamen University
  • Dana-Farber Cancer Institute
  • University of Cambridge
  • Radboud University Nijmegen
  • Comprehensive Cancer Center
  • University of California at Irvine
  • Byelorussian Institute for Oncology and Medical Radiology Aleksandrov N.N.
  • Rutgers - The State University of New Jersey, New Brunswick
  • Oregon Health and Science University
  • Friedrich-Alexander University Erlangen-Nürnberg
  • Duke University
  • Memorial Sloan-Kettering Cancer Center
  • University of Bergen
  • Hannover Medical School
  • National Institutes of Health
  • Provincial Health Services Authority
  • Simon Fraser University
  • Cancer Council Victoria
  • University of Helsinki
  • Helsinki University Hospital
  • Peter Maccallum Cancer Centre
  • University of Melbourne
  • Beatson Oncology Centre
  • German Cancer Research Center
  • Queensland Institute of Medical Research
  • Moffitt Cancer Center
  • University of New Mexico
  • Harvard University
  • Mayo Clinic Rochester, MN
  • Pomeranian Medical University in Szczecin
  • Dartmouth College
  • Kliniken Essen-Mitte
  • Dr. Horst Schmidt Klinik GmbH
  • Friedrich Schiller University Jena
  • University of Southampton
  • University of Pittsburgh
  • University of California at Los Angeles
  • University of Kansas
  • Shanghai Cancer Institute
  • University College London
  • Cedars-Sinai Medical Center
  • Sime Darby Medical Centre
  • University of Texas MD Anderson Cancer Center
  • Danish Cancer Society
  • University of Copenhagen
  • Aichi Cancer Center Hospital and Research Institute
  • Medical University of South Carolina
  • Flanders Institute for Biotechnology
  • KU Leuven
  • Roswell Park Cancer Institute
  • Texas Southern University
  • Maria Sklodowska-Curie Institute of Oncology
  • Kyushu University
  • Stanford University
  • University of Toronto
  • University of Glasgow
  • University of Texas Health Science Center at Houston
  • University of Malaya
  • Yale University
  • University Health Network
  • Fred Hutchinson Cancer Research Center
  • University of Washington
  • Institut für Humangenetik Wiesbaden
  • Vanderbilt University
  • University of Hawai'i at Mānoa
  • NHS Greater Glasgow and Clyde
  • Medical University of Warsaw
  • Ulm University
  • The University of Sydney

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

Genome-wide association studies have reported 11 regions conferring risk of high-grade serous epithelial ovarian cancer (HGSOC). Expression quantitative trait locus (eQTL) analyses can identify candidate susceptibility genes at risk loci. Here we evaluate cis-eQTL associations at 47 regions associated with HGSOC risk (P≤10-5). For three cis-eQTL associations (P<1.4 × 10-3, FDR<0.05) at 1p36 (CDC42), 1p34 (CDCA8) and 2q31 (HOXD9), we evaluate the functional role of each candidate by perturbing expression of each gene in HGSOC precursor cells. Overexpression of HOXD9 increases anchorage-independent growth, shortens population-doubling time and reduces contact inhibition. Chromosome conformation capture identifies an interaction between rs2857532 and the HOXD9 promoter, suggesting this SNP is a leading causal variant. Transcriptomic profiling after HOXD9 overexpression reveals enrichment of HGSOC risk variants within HOXD9 target genes (P=6 × 10-10 for risk variants (P<10-4) within 10 kb of a HOXD9 target gene in ovarian cells), suggesting a broader role for this network in genetic susceptibility to HGSOC.

Original languageEnglish
Article number8234
JournalNature Communications
Volume6
DOIs
StatePublished - Sep 22 2015

Fingerprint

Dive into the research topics of 'Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer'. Together they form a unique fingerprint.

Cite this